Abstract 16777: Serial Angiographic Follow-Up after Successful Implantation of Sirolimus, Paclitaxel and Everolimus-Eluting Stent for Chronic Total Occlusions: Multicenter Registry in Asia
Purpose: To evaluate the long-term efficacy of Sirolimus-eluting stent (SES), Paclitaxel-eluting stent (PES) and Everolimus-eluting stent (EES) on the outcome of patients with chronic total occlusions (CTO).
Methods: A total of 298 patients with 326 CTO lesions (male 72.1%, mean age 69.8 yrs, LAD 49.7%, LCX 21.5%, RCA 26.7%, Others 2.1%) were treated with SES (102 patients 118 lesions, mean lesion length 36.1±12.9 mm, mean stent length 41.7±15.6 mm) EES (88 patients 94 lesions, mean lesion length 34.2±13.8 mm, mean stent length 40.1±14.8 mm) and PES (108 patients 114 lesions, mean lesion length 38.5±12.8 mm, mean stent length 43.9±19.5 mm). We conducted follow-up coronary angiogram in all patients after successful implantation of SES, PES and EES (9, 12, 18, 24 months respectively)
Results: See table for clinical results.
Conclusions: There is a different timing of late catch up phenomenon (late lumen loss) of SES, EES and PES (SES: 12–18 months, EES: 12–18 months and PES: 9–12 months) after successful implantation of SES, PES and EES in patients with chronic total occlusion. Patients treated with SES and EES showed lesser loss of minimum lumen diameter compared with PES.
- © 2010 by American Heart Association, Inc.